Search Result

Results for "

neuropsychiatric diseases

" in MedChemExpress (MCE) Product Catalog:

By Targets:	5-HT Receptor (5) Acetyl-CoA synthetase (1) Acyltransferase (1) Adrenergic Receptor (1) Arrestin (2) Biochemical Assay Reagents (1) Carbonic Anhydrase (1) Cholinesterase (ChE) (1) Dopamine Receptor (4) Drug Derivative (1) Drug Isomer (1) GABA Receptor (3) GPR52 (2) HDAC (1) Histamine Receptor (1) iGluR (1) mAChR (1) mGluR (1) Monoamine Transporter (1) Phosphodiesterase (PDE) (1) Phospholipase (1) Reference Standards (1) REV-ERB (1) Trace Amine-associated Receptor (TAAR) (2)
By Research Areas:	Cancer (2) Cardiovascular Disease (1) Infection (1) Inflammation/Immunology (4) Metabolic Disease (4) Neurological Disease (26)

By Targets:

5-HT Receptor (5)

Acetyl-CoA synthetase (1)

Acyltransferase (1)

Adrenergic Receptor (1)

Arrestin (2)

Biochemical Assay Reagents (1)

Carbonic Anhydrase (1)

Cholinesterase (ChE) (1)

Dopamine Receptor (4)

Drug Derivative (1)

Drug Isomer (1)

GABA Receptor (3)

GPR52 (2)

HDAC (1)

Histamine Receptor (1)

iGluR (1)

mAChR (1)

mGluR (1)

Monoamine Transporter (1)

Phosphodiesterase (PDE) (1)

Phospholipase (1)

Reference Standards (1)

REV-ERB (1)

Trace Amine-associated Receptor (TAAR) (2)

By Research Areas:

Cancer (2)

Cardiovascular Disease (1)

Infection (1)

Inflammation/Immunology (4)

Metabolic Disease (4)

Neurological Disease (26)

Cat. No.	Nombre del producto	Target	Áreas de investigación	Chemical Structure

HY-148104

ACSS2-IN-2 1 Publications Verification	Acetyl-CoA synthetase	Infection Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
ACSS2-IN-2 is an acyl-CoA synthetase short-chain family member 2 (ACSS2) inhibitor. ACSS2-IN-2 can inhibit ACSS2 activity with an IC₅₀ value of 3.8 nM. ACSS2-IN-2 can be used for the research of several diseases, such as viral infection, metabolic disorders, neuropsychiatric diseases, inflammatory/autoimmune conditions and cancer .

HY-117516

SR10067	REV-ERB	Neurological Disease Metabolic Disease
SR10067 is a potent, selective and brain penetrant REV-ERB agonist. SR10067 has high affinity for Rev-Erbβ and Rev-Erbα with IC₅₀ values of 160 nM and 170 nM, respectively. SR10067 can be used for the research of metabolic diseases and neuropsychiatric disorders .

HY-109112

Brilaroxazine RP5063	Dopamine Receptor 5-HT Receptor	Neurological Disease Inflammation/Immunology
Brilaroxazine (RP5603) is a potent and orally active multimodal dopamine (DA)/serotonin (5-HT) modulator. Brilaroxazine is a partial agonist of dopamine (DA) D2, D3, and D4 receptors, 5-HT1A (K_i=1.5 nM) and 5-HT2A (K_i=2.5 nM), and has antagonist activity at 5-HT2B (K_i=0.19 nM), and 5-HT7 (K_i=2.7 nM) receptors . Brilaroxazine is an atypical antipsychotic agent, and has the potential to improve cognitive impairments in neuropsychiatric and neurological diseases in vivo .

HY-19348

Pimelic Diphenylamide 106 5 Publications Verification RGFA-8; TC-H 106; Histone Deacetylase Inhibitor VII	HDAC Monoamine Transporter	Neurological Disease Cancer
Pimelic Diphenylamide 106 (TC-H 106) is a slow, tight binding class I HDAC inhibitor (inhibits HDAC1, 2, and 3 with IC₅₀ values of 150 nM, 760 nM, and 370 nM, respectively), with no activity against class II HDACs. Pimelic Diphenylamide 106 modulates dopamine concentration and protects dopamine cells by inducing VMAT2 expression. Pimelic Diphenylamide 106 can be used in the study of neuropsychiatric diseases such as attention deficit hyperactivity disorder (ADHD) .

HY-157521

AANAT-IN-1	Acyltransferase	Neurological Disease Metabolic Disease
AANAT-IN-1 is an arylalkylamine N-acetyltransferase (AANAT) inhibitor with a sheep AANAT IC₅₀ of 9.9 μM. AANAT-IN-1 binds to the active site of sheep AANAT, interacting with amino acid residues via hydrogen bonds, hydrophobic interactions, ionic interactions, and water bridges, inhibiting the enzyme's catalytic activity. AANAT-IN-1 can be used for the researches of circadian rhythm-associated neuropsychiatric conditions, seasonal affective disorder, and other diseases associated with abnormally elevated melatonin levels .

HY-125751

UCSF924 1 Publications Verification	Dopamine Receptor	Neurological Disease
UCSF924, a chemical probe, is a potent and specific dopamine D4 receptor (DRD4) partial agonist with a EC₅₀ of 4.2 nM. UCSF924 has no off-target effects on more than 320 non-olfactory GPCRs. UCSF924 can be used for research in the field of neuropsychiatric diseases .

HY-176900

GPR52 agonist-4	GPR52	Neurological Disease
GPR52 agonist-4 (Compound 65) is a highly selective G-protein-coupled receptor GPR52 modulator. GPR52 agonist-4 is promising for research of neuropsychiatric diseases .

HY-163671

PW0729	GPR52 Arrestin	Neurological Disease
PW0729 is a selective GPR52 agonist. PW0729 activates G protein/cAMP signaling pathway, with bias toward this pathway over β-arrestin recruitment, and induces GPR52 desensitization. PW0729 can be used for the research of neuropsychiatric and neurological diseases .

HY-179291

5-HT2A agonist 8	5-HT Receptor	Neurological Disease
5-HT2A agonist 8 (Compound 67) is a 5-HT_2A agonist, with an EC₅₀ of 4 nM. 5-HT2A agonist 8 can be used in the research of neuropsychiatric and neurodegenerative diseases .

HY-128856

P7C3-OMe	Drug Derivative	Neurological Disease
P7C3-OMe is a pro-neurogenic compound, has therapeutic benefits in neuropsychiatric and/or neurodegenerative disease. The R-enantiomer of P7C3-OMe is far more active than the S-enantiomer .

HY-103522

AA29504	GABA Receptor	Neurological Disease
AA29504 is a ethyl carbamate with γ-aminobutyric acid (GABAA(HY-L120) receptor activity. AA29504 inhibits the delivery of the neurotransmitter gamma-aminobutyric acid in the central nervous system. AA29504 can be used to research anxiety, insomnia and other neuropsychiatric diseases .

HY-169951

Lu AF90103	iGluR	Neurological Disease
Lu AF90103 (Compound 42e) is a methyl ester prodrug of compound 42d capable of penetrating the blood-brain barrier. Compound 42d acts as a partial agonist of the GluN1/GluN2B complex, exhibiting 24% efficacy, and has an EC₅₀ value of 78 nM. Lu AF90103 plays an important role in neuropsychiatric diseases research .

HY-15977

(S)-P7C3-OMe	Drug Isomer	Neurological Disease
(S)-P7C3-OMe, P7C3-A20 hydroxylated analog, is the (S)-enantiomer of P7C3-OMe. P7C3-OMe is a pro-neurogenic compound, can be used for the research of neuropsychiatric and/or neurodegenerative disease .

HY-174152

GABAB receptor antagonist 5	GABA Receptor	Neurological Disease
GABAB receptor antagonist 5 (Compound 23) is a competitive GABA_B receptor antagonist. GABAB receptor antagonist 5 is promising for research of neuropsychiatric diseases, such as epilepsy, depression, and addiction .

HY-W909149

TAAR1 agonist 3	Trace Amine-associated Receptor (TAAR) Adrenergic Receptor	Neurological Disease
TAAR1 agonist 3 is a trace amine-associated receptor 1 (TAAR1) agonist (pEC₅₀=7.6). TAAR1 agonist 3 is also a full agonist of the α_2A receptor (pEC₅₀=6). TAAR1 agonist 3 can be used in the study of neuropsychiatric diseases .

HY-W909173

TAAR1 agonist 2	Trace Amine-associated Receptor (TAAR) Histamine Receptor mAChR	Neurological Disease
TAAR1 agonist 2 (compound 30) is a full agonist of trace amine-associated receptor 1 (TAAR1) (pEC₅₀=7.5). TAAR1 agonist 2 also exhibits agonist activity at H1 receptors and activates several members of the muscarinic acetylcholine receptor family, such as the M2 receptor (pEC₅₀=5). TAAR1 agonist 2 can be used in the study of neuropsychiatric diseases .

HY-120662

GSK1331268	mGluR	Neurological Disease
GSK1331268 is a selective, orally active agonist for mGluR2 with a pEC₅₀ of 6.9. GSK1331268 exhibits good blood-brain barrier penetration. GSK1331268 regulates glutamate signaling, and can be used in research of neurodegenerative and neuropsychiatric diseases .

HY-E70395

Prolyl endopeptidase PE; PEP	Biochemical Assay Reagents	Neurological Disease
Prolyl Endopeptidase, highly active in brain and other tissues, catabolizes proline-containing peptides such as substance P, neurotensin, luteinizing hormone-releasing hormone, thyrotropin releasing hormone, bradykinin and angiotensin II. Prolyl Endopeptidase can be used for study of neuropsychiatric diseases such as stress disorder, depression, and schizophrenia .

HY-178103

D1R antagonist 2	Dopamine Receptor Arrestin	Neurological Disease
D1R antagonist 2 (Compound 13a) is a BBB-penetrable D1R antagonist with IC₅₀s of 35.6 and 70 nM for cAMP-based D1R and β-arrestin-based D1R, respectively. D1R antagonist 2 effectively antagonizes D1R-mediated cAMP and β-arrestin recruitment. D1R antagonist 2 can be used for neurodegenerative and neuropsychiatric diseases such as schizophrenia, Parkinson’s disease and Alzheimer’s disease research .

HY-169163

BChE-IN-36	Carbonic Anhydrase Cholinesterase (ChE)	Neurological Disease
hBChE-IN-4 (compound 40) is a potent hCA activator and BChE inhibitor with K_A values of 266, 76.9, 918, 893, 98.0 nM for hCA I, hCA II, hCA IV, hCA VB, hCA VII, IC₅₀ values of 72.1, 4.2 nM for eeAChE, eqBChE, respectively. hBChE-IN-4 shows no cytotoxicity. hBChE-IN-4 shows potent procognitive effects. hBChE-IN-4 has the potential for the research of neurodegenerative diseases and other neuropsychiatric disorders .

HY-174146

5-HT1A agonist 1	5-HT Receptor	Neurological Disease
5-HT1A agonist 1 (Compound Ex.37) is a highly selective 5-HT_1a receptor agonist (EC₅₀=0.18 nM). 5-HT1A agonist 1 mimicks serotonin binding to the receptor, promotes postsynaptic membrane hyperpolarization, inhibits neuronal hyperexcitability, and reduces the release of anxiety-related neurotransmitters. 5-HT1A agonist 1 is promising for research of neuropsychiatric diseases .

HY-176717

5-HT1AR agonist 3	5-HT Receptor	Neurological Disease
5-HT1AR agonist 3 (Compound 77) is a 5-HT1A agonist. 5-HT1AR agonist 3 has 5-HT1A receptor agonist activity (EC₅₀: 1.3 nM). 5-HT1AR agonist 3 mainly exerts its effects by activating 5-HT1A receptors and can be used in the study of neuropsychiatric diseases such as anxiety, depression and sleep disorders .

HY-109112R

Brilaroxazine (Standard) RP5063 (Standard)	Reference Standards Dopamine Receptor 5-HT Receptor	Neurological Disease Inflammation/Immunology
Brilaroxazine (Standard) is the analytical standard of Brilaroxazine. This product is intended for research and analytical applications. Brilaroxazine (RP5603) is a potent and orally active multimodal dopamine (DA)/serotonin (5-HT) modulator. Brilaroxazine is a partial agonist of dopamine (DA) D2, D3, and D4 receptors, 5-HT1A (K_i=1.5 nM) and 5-HT2A (K_i=2.5 nM), and has antagonist activity at 5-HT2B (K_i=0.19 nM), and 5-HT7 (K_i=2.7 nM) receptors . Brilaroxazine is an atypical antipsychotic agent, and has the potential to improve cognitive impairments in neuropsychiatric and neurological diseases in vivo .

HY-160637

Lp-PLA2-IN-17	Phospholipase	Cardiovascular Disease Neurological Disease Metabolic Disease Inflammation/Immunology
Lp-PLA2-IN-17 (Compound 39) is an inhibitor of Lp-PLA₂. Lp-PLA2-IN-17 can be used to study disorders involving the hydrolysis of oxidized lipids into two inflammatory substances with the participation of Lp-PLA₂ .

HY-123446

JNJ-42259152	Phosphodiesterase (PDE)	Neurological Disease
JNJ-42259152 is a phosphodiesterase 10A (PDE10A) positron emission tomography (PET) tracer that is specific for PDE10A activity. JNJ-42259152 can be dynamically scanned in healthy volunteers to assess its kinetic properties in the brain. The half-life of JNJ-42259152 in the blood is an average of 90 minutes. JNJ-42259152 has demonstrated reliable binding potential (BPND) in different target areas (such as the lentiform nucleus, caudate nucleus, ventral striatum, etc.), providing an important tool for studying neuropsychiatric diseases .

HY-182944

GATT-44	GABA Receptor	Neurological Disease
GATT-44 is a blood-brain barrier-permeable, selective GABA transporter 1 (GAT-1) ligand with an IC₅₀ of 126 nM. GATT-44 shows selectivity for GAT-2, GAT-3 and BGT-1 subtypes, and undergoes copper-mediated ¹⁸F-radiofluorination. The radiolabeled GATT-44 ([ ¹⁸F]GATT-44) exhibits brain uptake, metabolic stability and high GAT-1 binding specificity in non-human primates. GATT-44 is applicable for research on neurodegenerative and neuropsychiatric diseases .

Consulta en línea

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Saludo			Country or Region *
Nombre del solicitante *			Nombre de la Organizaciòn *
Department *
Direcciòn del E-mail *			Nombre del producto *
Cat. No.			Requested quantity *
Número de teléfono *
Observaciones

Consulta en línea

Inquiry Information

Nombre del producto:
Cat. No.:
Cantidad:
MCE Japan Authorized Agent:

Name
E-mail *

	Sorry, but the email address you supplied was invalid.

neuropsychiatric diseases

Inhibitors & Agonists